TGTX | tickerfilter.com

Fundamental analysis

40%

Profitability 25%

Dept financing 32%

Liquidity 50%

Performance 55%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

7.76%

1 Month

21.38%

3 Months

17.07%

6 Months

4.94%

1 Year

-0.03%

2 Year

162.13%

Key data

Stock price

$36.96

P/E Ratio

N/A

DAY RANGE

$35.16 - $37.16

EPS

$3.10

52 WEEK RANGE

$25.28 - $46.48

52 WEEK CHANGE

-$2.71

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

159.688 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-05-2025

BETA

1.40

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,777,770

AVERAGE 30 VOLUME

$1,795,221

Company detail

CEO: Michael S. Weiss
Region: US
Website: tgtherapeutics.com
Employees: 290
IPO year: 2006

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.

TGTX - TG THERAPEUTICS, INC.